Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells

Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells

Non-small cell lung cancer (NSCLC) is often characterized by an underlying mutation in the epidermal growth factor receptor (EGFR), contributing to aggressive metastatic disease. Methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate (CDODA-Me), a glycyrrhetinic acid derivative, reportedly improve...

Full description

Bibliographic Details
Main Authors:	Ebony Nottingham, Elizabeth Mazzio, Sunil Kumar Surapaneni, Shallu Kutlehria, Arindam Mondal, Ramesh Badisa, Stephen Safe, Arun K. Rishi, Mandip Singh
Format:	Article
Language:	English
Published:	Elsevier 2021-12-01
Series:	Journal of Pharmaceutical Analysis
Subjects:	Transcriptomic analysis Combination therapy Drug resistance Erlotinib Epidermal growth factor receptor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2095177921000629

Similar Items

Erlotinib-induced dry eye
by: Rashmita Ravisankar, et al.
Published: (2023-01-01)

Treatment of TRPV3 mutation-associated Olmsted syndrome with erlotinib
by: Kathleen E. Spitz, MD, MBA, et al.
Published: (2022-07-01)

Modified Synthesis of Erlotinib Hydrochloride
by: Leila Barghi, et al.
Published: (2012-06-01)

Scalp acneiform rash caused by erlotinib: a case report
by: Zhang Qian, Zhang Xin, Wang Qian, Zhou Xiyuan, Zhang Lixia
Published: (2023-07-01)

Development and Application of an HPLC Method for Erlotinib Protein Binding Studies
by: Soheila Bolandnazar, et al.
Published: (2013-08-01)

OCTA analysis of the effect of Erlotinib on corneal thickness in mice
by: Qing Yuan, et al.
Published: (2019-08-01)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015-09-01)

Stability and Formulation of Erlotinib in Skin Creams
by: David Nguyen, et al.
Published: (2022-02-01)

Spontaneous Healing of Corneal Perforation after Temporary Discontinuation of Erlotinib Treatment
by: Naoyuki Morishige, et al.
Published: (2014-01-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)

Tumor Cell-Specific Retention and Photodynamic Action of Erlotinib-Pyropheophorbide Conjugates
by: Erin C. Tracy, et al.
Published: (2022-09-01)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
by: Atakan Topcu, et al.
Published: (2022-10-01)

Cutaneous side effects during therapy with Erlotinib: Case report
by: Jovičić Sanja, et al.
Published: (2021-01-01)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
by: Cavazzoni Andrea, et al.
Published: (2012-12-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer
by: Jinhui TIAN, et al.
Published: (2009-12-01)

The Analysis of Erlotinib on Brain Metastases in Patients with Non-small-cell Lung Cancer
by: Baohui HAN, et al.
Published: (2009-12-01)

Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
by: Haiqing YUAN, et al.
Published: (2009-07-01)

Acute Fatal Liver Toxicity under Erlotinib
by: Sabina Schacher-Kaufmann, et al.
Published: (2010-06-01)

Development and validation of RP-HPLC method for the estimation of Erlotinib in pharmaceutical formulation
by: S.T. Latha, et al.
Published: (2017-02-01)

Erlotinib in Patients with Advanced Non-small Cell Lung Cancer in Middle Eastern Population
by: Abdul Rahman Jazieh, et al.
Published: (2018-07-01)

A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer
by: Mingzhi LI, et al.
Published: (2009-12-01)

Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer and COPD
by: Huiling ZHANG, et al.
Published: (2009-12-01)

A Retrospective Analysis of Erlotinib and TP/GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer
by: Yongjuan WU, et al.
Published: (2009-12-01)

Stabilizing Effect of Soluplus on Erlotinib Metastable Crystal Form in Microparticles and Amorphous Solid Dispersions
by: Shuyu Jia, et al.
Published: (2022-03-01)

The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis
by: Fazong Wu, et al.
Published: (2019-08-01)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
by: Long-fei Mao, et al.
Published: (2022-04-01)

Vorinostat enhances the therapeutic potential of Erlotinib via MAPK in lung cancer cells
by: Amany I Alqosaibi, et al.
Published: (2022-01-01)

Four Cases of Interstitial Lung Disease Induced by Erlotinib  and A Review of the Literatures
by: Xiaoling WU, et al.
Published: (2012-08-01)

Dramatic Improvement of Severe Cicatricial Ectropion after Discontinuing Long-Term Erlotinib Therapy in a Patient with Lung Cancer
by: Mehmet Serhat Mangan
Published: (2022-02-01)

Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase
by: Neha Sharma, et al.
Published: (2020-09-01)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
by: Ruijian Li, et al.
Published: (2023-08-01)

Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy
by: Wafa K. Fatani, et al.
Published: (2023-05-01)

The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line
by: Anna Svedberg, et al.
Published: (2020-04-01)

Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer
by: Yunjian HUANG, et al.
Published: (2009-12-01)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
by: Andrew J. Wiele, et al.
Published: (2021-04-01)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
by: Natthaporn Sueangoen, et al.
Published: (2020-03-01)

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors
by: Xi-xi Hou, et al.
Published: (2022-08-01)

Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer
by: Natsuko Komiya, et al.
Published: (2021-03-01)

Novel Erlotinib–Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms
by: József Murányi, et al.
Published: (2023-02-01)